WO2006088464A3 - A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection - Google Patents

A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection Download PDF

Info

Publication number
WO2006088464A3
WO2006088464A3 PCT/US2005/005405 US2005005405W WO2006088464A3 WO 2006088464 A3 WO2006088464 A3 WO 2006088464A3 US 2005005405 W US2005005405 W US 2005005405W WO 2006088464 A3 WO2006088464 A3 WO 2006088464A3
Authority
WO
WIPO (PCT)
Prior art keywords
current invention
antibodies
antibody
radioimmunodetection
conjugated
Prior art date
Application number
PCT/US2005/005405
Other languages
French (fr)
Other versions
WO2006088464A2 (en
Inventor
Scott E Strome
Daniel Schindler
Lieping Chen
Harry Meade
Yann Echelard
Original Assignee
Gtc Biotherapeutics Inc
Scott E Strome
Daniel Schindler
Lieping Chen
Harry Meade
Yann Echelard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/058,458 external-priority patent/US20060182744A1/en
Priority claimed from PCT/US2005/004739 external-priority patent/WO2006088447A1/en
Application filed by Gtc Biotherapeutics Inc, Scott E Strome, Daniel Schindler, Lieping Chen, Harry Meade, Yann Echelard filed Critical Gtc Biotherapeutics Inc
Priority to EP05723386A priority Critical patent/EP1850872A4/en
Publication of WO2006088464A2 publication Critical patent/WO2006088464A2/en
Publication of WO2006088464A3 publication Critical patent/WO2006088464A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.
PCT/US2005/005405 2005-02-15 2005-02-18 A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection WO2006088464A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05723386A EP1850872A4 (en) 2005-02-15 2005-02-18 A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
USPCT/US2005/04739 2005-02-15
US11/058,458 US20060182744A1 (en) 2005-02-15 2005-02-15 Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
PCT/US2005/004739 WO2006088447A1 (en) 2005-02-15 2005-02-15 An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
US11/058,458 2005-02-17

Publications (2)

Publication Number Publication Date
WO2006088464A2 WO2006088464A2 (en) 2006-08-24
WO2006088464A3 true WO2006088464A3 (en) 2007-11-15

Family

ID=36975599

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005405 WO2006088464A2 (en) 2005-02-15 2005-02-18 A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection

Country Status (2)

Country Link
EP (1) EP1850872A4 (en)
WO (1) WO2006088464A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1945666T3 (en) * 2005-10-21 2013-07-01 Genzyme Corp Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods for their preparation and use thereof
AU2012201010B2 (en) * 2005-10-21 2015-01-22 Genzyme Corporation Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use
EP2279003A4 (en) * 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
MX2015010427A (en) 2013-02-13 2016-03-17 Lab Francais Du Fractionnement Highly galactosylated anti-tnf-alpha antibodies and uses thereof.
CN103713125B (en) * 2014-01-08 2015-12-30 滨州医学院 A kind of for detect malignant hematologic disease CD137L suddenly change kit and application
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
EP4225792A1 (en) 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
WO2024056862A1 (en) 2022-09-15 2024-03-21 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US20050013811A1 (en) * 2001-10-09 2005-01-20 Lieping Chen Enhancement of immune responses by 4-1bb-binding agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US20050013811A1 (en) * 2001-10-09 2005-01-20 Lieping Chen Enhancement of immune responses by 4-1bb-binding agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1850872A4 *

Also Published As

Publication number Publication date
WO2006088464A2 (en) 2006-08-24
EP1850872A4 (en) 2008-10-15
EP1850872A2 (en) 2007-11-07

Similar Documents

Publication Publication Date Title
EP2399935A3 (en) An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
WO2006088464A3 (en) A method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection
PH12019500270A1 (en) Combination therapy for cancer
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
ZA200500363B (en) Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
WO2006099141A3 (en) Anti-mesothelin antibodies
IL184617A0 (en) Dr5 antibodies and uses thereof
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
MX2015007343A (en) Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity.
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
WO2006044643A3 (en) Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2005032454A3 (en) Anti-muc-1 single chain antibodies for tumor targeting
MX2009009926A (en) Monoclonal human tumor-specific antibody.
WO2006116451A3 (en) Antibodies with immune effector activity and that internalize in endosialin-positive cells
WO2008118733A3 (en) Methods of treating cancer by administering human il-18 combinations
WO2021090062A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
TW200517124A (en) Fully human antibodies against human 4-1BB
WO2005011605A3 (en) Combination therapies for multiple sclerosis
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
Hiramatsu et al. CpG oligodeoxynucleotides potentiate the antitumor activity of anti‐BST 2 antibody
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2003061571A3 (en) Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005723386

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005723386

Country of ref document: EP